Acebutolol-induced subacute cutaneous lupus erythematosus

Skin Pharmacology and Physiology

Volumn 18, Issue 5, 2005, Pages 230-233

  Fenniche, S ^a   Dhaoui, A ^a   Ben Ammar, F ^a   Benmously, R ^a   Marrak, H ^a   Mokhtar, I ^a  

^a HABIB THAMEUR HOSPITAL   (Tunisia)

Author keywords

Acebutolol; Beta blocking medications; Lupus erythematosus; Subacute lupus erythematosus

Indexed keywords

ACEBUTOLOL; ANTINUCLEAR ANTIBODY; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; RO ANTIBODY;

ADULT; ARM; ARTICLE; CASE REPORT; ERYTHEMA; FACE; FEMALE; HUMAN; HYPERTENSION; IMMUNOLOGY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SEROLOGY; SKIN DEFECT; SKIN LUPUS ERYTHEMATOSUS; TRUNK;

ACEBUTOLOL; ADRENERGIC BETA-ANTAGONISTS; ANTIBODIES, ANTINUCLEAR; FEMALE; HUMANS; HYPERTENSION; LUPUS ERYTHEMATOSUS, CUTANEOUS; MIDDLE AGED;

EID: 23844475055     PISSN: 16605527     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086668     Document Type: Article

References (47)

1. Hess E: Drug-related lupus. N Engl J Med 1988;318:1460-1462.
2. Price EJ, Venables PTW: Drug-induced lupus. Drug Saf 1995;12:283-290.
3. Sontheimer RD, Thomas JR, Gilliam JN: Subacute cutaneous lupus erythematosus: A cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol 1979;115:1409-1415.
4. Provost TT, Watson R, Simmons-O'Brien E: Significance of the anti-Ro(SS-A) antibody in evaluation of patients with cutaneous manifestations of a connective tissue disease. J Am Acad Dermatol 1996;35:147-169.
5. Reed BR, Huff JC, Jones SK, Orton PW, Lee LA, Norris DA: Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med 1985;103:49-51.
6. Raftery EB, Denman AM: Systemic lupus erythematosus syndrome induced by practolol. Br Med J 1973;2:452-455.
7. Milner GR, Holt PJL, Bottomley J, Maciver JE: Practolol therapy associated with a systemic lupus erythematosus-like syndrome and an inhibitor to factor XIII. J Clin Pathol 1977;30:770-773.
8. Simon P, Aubert F, Boivin M, Bonn F, Mery JP: Syndrome lupique induit par un bêtabloquant. Nouv Presse Med 1981;10:105.
9. Taylor AE, Hindson C, Wacks H: A drug eruption due to acebutolol with combined lichenoid and lupus erythematosus features. Clin Exp Dermatol 1982;7:219-221.
10. Record NB Jr: Acebutolol-induced pleuropulmonary lupus syndrome. Ann Intern Med 1981;95:326-327.
11. Hourdebaigt-Larrusse P, Ziza JM, Grivaux M: Une nouvelle observation de lupus induit par acebutolol. Ann Cardiol Angeiol (Paris) 1985;34:421-423.
12. Bigot MC, Trenque T, Moulin M, Beguin J, Loyau G: Acebutolol-induced lupus syndrome. Therapie 1984;39:571-575.
13. Brown RC, Cooke J, Losowski MS: SLE syndrome, probably induced by labetalol. Postgrad Med J 1981;57:189-190.
14. Harrison T, Sisca TS, Wood WH: Propranolol-induced lupus syndrome. Postgrad Med 1976;59:241-244.
15. Bensaïd J, Aldigier JC, Gualde N: Systemic lupus erythematosus syndrome induced by pindolol. Br Med J 1979;1:1603-1604.
16. McGuiness M, Frye RA, Deng JS: Atenolol-induced lupus erythematosus. J Am Acad Dermatol 1997;37:298-299.
17. Paladini G: Peyronie's disease and systemic lupus erythematosus syndrome associated with metoprolol administration. A case report. Int J Tissue React 1981;3:95-98.
18. Zamber RW, Starkebaum G, Rubin RL, et al: Drug induced systemic lupus erythematosus due to ophthalmic timolol. J Rheumatol 1992;19:977-979.
19. Cody RJ, Calabresse JH, Clouch GD, Tarasi RC, Bravo EL: Development of antinuclear antibodies during acebutolol therapy. Clin Pharmacol Ther 1979;25:800-805.
20. Booth RJ, Bullock JY, Wilson JD: Antinuclear antibodies in patients on acebutolol. Br J Clin Pharmacol 1980;9:515-517.
21. Wilson JD: Antinuclear antibodies and cardiovascular drugs. Drugs 1980;19:292-305.
22. Hess E: Drug-related lupus. N Engl J Med 1988;318:1460-1462.
23. Blomgren SE, Vaughan GH: The immunogenicity of photo-oxidized DNA and of the product of DNA and procainamide-induced lupus. Arthritis Rheum 1968;11:470.
24. Sherman JD, Love DE, Harrington JF: Anemia, positive lupus and rheumatoid factors with methyldopa. Arch Intern Med 1967;120:321-326.
25. Kendall MJ, Hawkins CF: Quinidine-induced systemic lupus erythematosus. Postgrad Med J 1970;46:729-731.
26. Dubois EL: Procainamide induction of a systemic lupus erythematosus-like syndrome. Medicine 1969;48:217-228.
27. Koffler D, Carr R, Agnello V, et al: Antibodies to polynucleotides in human sera: Antigenic specificity and relation to disease. J Exp Med 1971;134:294-312.
28. Sakurai Y, Kurrihara R, Takeuchi M, et al: A case of SLE-like syndrome and severe hemolytic anemia caused by methyldopa. Nippon Naika Gakkai Zasshi 1995;84:2069-2071.
29. Perry HM, Tane M, Carmody S, et al: Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. J Lab Clin Med 1970;76:114-125.
30. Naessberger L, Sjoholm AG, Jonsson H, et al: Autoantibodies against neutrophil cytoplasm components in systemic lupus erythematosus and in hydralazine-induced lupus. Clin Exp Dermatol 1990;81:380-383.
31. Batchelor JR, Welsh KI, Tinoco RM, et al: Hydralazine-induced systemic lupus erythematosus: Influence of HLA-DR and sex or susceptibility. Lancet 1980;24:1107.
32. Hofstra A: Metabolism of hydralazine: Relevance to drug-induced lupus. Drug Metab Rev 1994;26:485-505.
33. Von Schmiedeberg SH, Goebel C, Gleichmann E, et al: Neutrophils and drug metabolism. Science 1995;268:585.
34. Jiang X, Khursigara G, Rubin RL: Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science 1994;266:810-813.
35. Uetrecht JP: Mechanism of drug-induced lupus. Chem Res Toxicol 1988;1:134-143.
36. Bray VJ, Sterling GW, Schultz KT, et al: Antihistone antibody profile in sulfasalazine-induced lupus. J Rheumatol 1994;21:2157-2158.
37. Parodi A, Romagnoli M, Rebora A: Subacute cutaneous lupus erythematosus-like eruption caused by hydrochlorothiazide. Photodermatology 1989;6:100-102.
38. Crowson AN, Magro CM: Subacute cutaneous lupus erythematosus arising in the setting of calcium channel blocker therapy. Hum Pathol 1997;28:67-73.
39. Ratliff NB: Captopril induced lupus. J Rheumatol 2002;29:1807-1808.
40. Brooke R, Coulson IH, Al Dawoud A: Terbinafine-induced subacute cutaneous lupus erythematosus. Br J Dermatol 1998;139:1132-1133.
41. Bonsmann G, Schiller M, Luger TA, Ständer S: Terbinafine-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2001;44:925-931.
42. Miyagawa S, Okuchi T, Shiomi Y, Sakamoto K: Subacute cutaneous lupus erythematosus lesions precipitated by griseofulvin. J Am Acad Dermatol 1989;21:343-346.
43. Provost TT, Watson R, Simmons-O'Brien E: Significance of the anti-Ro(SSA) antibody in evaluation of patients with cutaneous manifestations of a connective tissue disease. J Am Acad Dermatol 1996;35:147-169.
44. Toll A, Campo-Pisa P, Gonzales-Castro J, et al: Subacute cutaneous lupus erythematosus associated with cinnarizine and thiethylperazine therapy. Lupus 1998;7:364-366.
45. Fernandez-Diaz ML, Herranz P, Suarez-Marrero MC, Borbujo J, Manzano R, Casado M: Subacute cutaneous lupus erythematosus associated with cilazapril. Lancet 1995;345:398.
46. Nousari HC, Kimyai-Asadi A, Tausk FA: Subacute cutaneous lupus erythematosus associated with interferon beta-1a. Lancet 1998;352:1825-1826.
47. Crowson AN, Magro CM: Lichenoid and subacute cutaneous lupus erythematosus-like dermatitis associated with antihistamine therapy. J Cutan Pathol 1999;26:95-99.